AKT1 and colorectal carcinoma: Thus, the findings indicate that the combination of SHP2 and a FAK inhibitor may be a board-spectrum and promising treatment regimen for CRC, and the potential working mechanism of the combination therapy on AKT pathway is represented in Figure 7.